Serina Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Serina Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q2 2024.
  • Serina Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$3.87M, a 309% decline year-over-year.
  • Serina Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$14.2M, a 170% decline year-over-year.
  • Serina Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$9.89M, a 41.7% decline from 2022.
  • Serina Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$6.98M, a 12.1% increase from 2021.
  • Serina Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$7.93M, a 21.5% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$14.2M -$3.87M -$2.92M -309% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$11.2M -$2.32M -$1.36M -141% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$9.89M -$5.62M -$3.84M -216% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-22
Q3 2023 -$6.05M -$2.36M -$806K -52% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$5.24M -$945K +$646K +40.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$5.89M -$962K +$1.09M +53.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$6.98M -$1.78M +$85K +4.55% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-22
Q3 2022 -$7.06M -$1.55M +$124K +7.41% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$7.18M -$1.59M +$614K +27.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$7.8M -$2.05M +$135K +6.17% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$7.93M -$1.87M +$460K +19.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$8.39M -$1.67M +$723K +30.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$9.12M -$2.21M +$163K +6.88% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$9.28M -$2.19M +$821K +27.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$10.1M -$2.33M +$389K +14.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-29
Q3 2020 -$10.5M -$2.4M +$882K +26.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$11.4M -$2.37M +$1.07M +31.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$12.4M -$3.01M +$114K +3.65% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$12.6M -$2.72M +$642K +19.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$13.2M -$3.28M -$1.08M -48.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$12.1M -$3.44M -$1.31M -61.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$10.8M -$3.12M +$429K +12.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$11.2M -$3.36M Oct 1, 2018 Dec 31, 2018 10-K/A 2020-03-31
Q3 2018 -$2.2M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$2.13M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$3.55M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.